3302 (3302) Fair Value & Analysis

Industrials · Market cap HK$331M

3 3302 3302 · HK

PriceHK$0.3700

Fair ValueHK$0.3000

Upside-18.9%

Quality58/100

Watch 3302 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.1900 – HK$0.4000

Fair value as of: Jul 2, 2026

From 3 valuation models · updated today

Share price +2.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1200 – HK$0.5000 · fair‑value band HK$0.1900 – HK$0.4000 · the HK$0.3700 price screens above the HK$0.3000 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

3302 (3302) currently trades at HK$0.3700, while our model-based Fair Value estimate is HK$0.3000 — implying the stock looks roughly 18.9% overvalued today. We read business quality at 58/100 (solid quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 3302 generated revenue of HK$106M at a net margin of -6.9%. Revenue grew 17.6% year over year. It earns a return on equity of -6.7%. Net debt stands at HK$13.5M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$106M

Revenue growth (YoY) +17.6%

Net margin -6.9%

Return on equity -6.7%

Free cash flow −HK$4.2M FY2025

Operating margin -7.1%

More key figures

EPS growth (YoY) -72.8%

Net debt HK$13.5M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3302 reported revenue of HK$106M in FY2025 versus HK$168M in FY2021, a compound −10.9%/yr. Reported net income was −HK$7.3M in FY2025.

Revenue −10.9%/yr

FY21 HK$168M

FY22 HK$124M

FY23 HK$92.5M

FY24 HK$99.0M

FY25 HK$106M

Net income

FY21 HK$11.9M

FY22 HK$4.6M

FY23 −HK$2.6M

FY24 −HK$6.3M

FY25 −HK$7.3M

Is 3302 fairly valued? → Check now

Similar stocks

6 more Specialty Industrial Machinery stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
GE Vernova Inc GEV	$1,128	$185.61	-84%
SIEGY SIEGY	$155.10	$88.93	-43%
SMAWF SMAWF	$307.12	$176.28	-43%
SMNS SMNS	C$31.76	C$22.85	-28%
SIE SIE	€258.40	€144.67	-44%
Schneider Electric S.E. SBGSF	$334.00	$148.44	-56%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 3302 (3302) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.3000 versus a price of HK$0.3700 — about −19% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 3302?

Our model-based fair value for 3302 is HK$0.3000 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.3700.

What is the quality score of 3302?

3302 has a Quality Score of 58/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 3302 (3302)?

3302 reported trailing-twelve-month revenue of about HK$106M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 3302?

The net profit margin of 3302 is about -6.9%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.